In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Desmopressin | Natural peptide Oxytocin | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Natural peptide | |
| Area | Sexual health and hormones | Sexual health and hormones | |
| Evidence | |||
| Amount of evidence | 695 | 3,492 (plus 1,148 on natural levels, listed separately) | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 86 (81 in people) | 157 (152 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 102 · 14 active19 more mention it but do not test it | 690 · 65 active238 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Ddavp says: “Antidiuretic replacement in central diabetes insipidus, temporary polyuria and polydipsia after head trauma or pituitary-region surgery, and primary nocturnal enuresis”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Desmopressin | Oxytocin |
|---|---|---|
| Cognition and memoryNervous system and cognition | 77 | 41440311 |
| Bleeding and clottingWhole body |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Pitocin says: “Antepartum: medically indicated induction of labor, stimulation or reinforcement of labor, adjunctive therapy in incomplete or inevitable abortion” No central EU authorisation (EMA).
19218210
20182 |
| Adverse eventsWhole body | 73721 | 1261233 |
|---|
| Receptor activity and mechanismKidney and urinary | 1037 | 28960801472 |
|---|
| PainWhole body | 99 | 1098524 |
|---|
| PharmacokineticsPharmacology | 22814 | 9168203 |
|---|
| Stress hormonesEndocrine and hormones | 11 | 7560123 |
|---|
| Sex hormones and fertilityEndocrine and hormones | 33 | 150328632 |
|---|
| Heart functionCardiovascular | 541 | 76353110 |
|---|
| Psychiatric symptomsMental health and mood | 11 | 4343 |
|---|
| Blood pressureCardiovascular | 77 | 5219249 |
|---|
| SleepSleep | 1313 | 1091 |
|---|
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 102 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Ferring Pharmaceuticals799 participantsMay 2007 to Feb 2008
Nocturia
Ferring Pharmaceuticals554 participantsDec 2007 to May 2010
Nocturia
Ferring Pharmaceuticals395 participantsFeb 2011 to Jan 2012
Nocturia
19 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 690 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
University of Alabama at Birmingham1,798 participantsNov 2008 to Jun 2010
Uterine Atony · Postpartum Hemorrhage
Northwestern University1,003 participants28 Sept 2015 to 28 Sept 2020
Dystocia
University of Zimbabwe506 participants8 Apr 2018 to 30 Jun 2019
Post Partum Hemorrhage
238 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Desmopressin | Oxytocin |
|---|---|---|
| Bleeding and clottingReproductive and sexual healthCompared as: value in the arm that got the peptide, in ml | −865 ml Median blood loss within 24 hours · Shown as a change. The study reports a median blood loss within 24 hours of this size. Placebo group: −738 ml Dose studied: 0.3 microgram per kilogramn = 1501989 | −508 ml Blood loss · Shown as a change. The study reports a blood loss of this size. Placebo group: −451 ml n = 942005 |
−865 ml
Median blood loss within 24 hours · Shown as a change. The study reports a median blood loss within 24 hours of this size.
Placebo group: −738 ml
Dose studied: 0.3 microgram per kilogramn = 1501989
−508 ml
Blood loss · Shown as a change. The study reports a blood loss of this size.
Placebo group: −451 ml
n = 942005
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Desmopressin | Oxytocin |
|---|---|---|
| Treatment adherence and retentionMental health and moodCompared as: value in the arm that got the peptide, in children | 4 children Withdrawals 6 monthsn = 1422015 |
No comparable result 6 randomized-trial results measure it in another way or another unit. |
| PharmacokineticsPharmacologyCompared as: value in the arm that got the peptide, in effect size | No comparable result 6 randomized-trial results measure it in another way or another unit. | −1.12 effect size Effect size Dose studied: 48 IU/day6 weeksn = 1032020 |
|---|
| Blood pressureCardiovascularCompared as: difference from placebo, in p | 0.28 P P value, standing blood pressure DDAVP versus placebo Dose studied: 0.2 mgn = 302012 | No comparable result 13 randomized-trial results measure it in another way or another unit. |
|---|
| Heart functionCardiovascularCompared as: value in the arm that got the peptide, in beats/min | 101.9 beats/min Standing heart rate · after DDAVP 0.2 mg (SD 14.5) After placebo (SD 17.4): 109.2 beats/min Dose studied: 0.2 mgn = 302012 | No comparable result 29 randomized-trial results measure it in another way or another unit. |
|---|
| Receptor activity and mechanismNervous system and cognitionCompared as: value in the arm that got the peptide, in %.h | 4667 %.h von Willebrand Factor antigen GLS mean AUEC Dose studied: 0·3 μg/kgn = 212014 | No comparable result 57 randomized-trial results measure it in another way or another unit. |
|---|
| PainNervous system and cognitionCompared as: difference from placebo, in % | No comparable result 8 randomized-trial results measure it in another way or another unit. | −11% allodynic area change Dose studied: 100 µgn = 52023 |
|---|
| SleepSleepCompared as: difference from placebo, in min | ≈ 40 min Increase in time to first void from baseline Dose studied: 50 μg3 monthsn not reported2013 | No comparable result 8 randomized-trial results measure it in another way or another unit. |
|---|
| Intensive care and hospital outcomesWhole bodyCompared as: value in the arm that got the peptide, in days | 4.9 days Mean hospital stay Placebo group: 5.9 days Dose studied: 0.3 μg/kgn = 1622011 | No randomized trial result 1 result from other study designs. |
|---|
| Body weightMetabolic and weightCompared as: difference from placebo, in g | No randomized trial result 2 results from other study designs. | 196 g Difference in total fat Dose studied: 24 IU four times daily8 weeksn = 612024 |
|---|
| Sex hormones and fertilityEndocrine and hormonesCompared as: value in the arm that got the peptide, in % | No randomized trial result 3 results from other study designs. | 14.4% Mean percent change testosterone Dose studied: 24 IUn = 452020 |
|---|
| Cognition and memoryNervous system and cognitionCompared as: difference from placebo, in sd | No randomized trial result 7 results from other study designs. | 1.39 SD effect size n = 262017 |
|---|
4 children
Withdrawals
6 monthsn = 1422015
No comparable result
6 randomized-trial results measure it in another way or another unit.
No comparable result
6 randomized-trial results measure it in another way or another unit.
−1.12 effect size
Effect size
Dose studied: 48 IU/day6 weeksn = 1032020
0.28 P
P value, standing blood pressure DDAVP versus placebo
Dose studied: 0.2 mgn = 302012
No comparable result
13 randomized-trial results measure it in another way or another unit.
101.9 beats/min
Standing heart rate · after DDAVP 0.2 mg (SD 14.5)
After placebo (SD 17.4): 109.2 beats/min
Dose studied: 0.2 mgn = 302012
No comparable result
29 randomized-trial results measure it in another way or another unit.
4667 %.h
von Willebrand Factor antigen GLS mean AUEC
Dose studied: 0·3 μg/kgn = 212014
No comparable result
57 randomized-trial results measure it in another way or another unit.
No comparable result
8 randomized-trial results measure it in another way or another unit.
−11%
allodynic area change
Dose studied: 100 µgn = 52023
≈ 40 min
Increase in time to first void from baseline
Dose studied: 50 μg3 monthsn not reported2013
No comparable result
8 randomized-trial results measure it in another way or another unit.
4.9 days
Mean hospital stay
Placebo group: 5.9 days
Dose studied: 0.3 μg/kgn = 1622011
No randomized trial result
1 result from other study designs.
No randomized trial result
2 results from other study designs.
196 g
Difference in total fat
Dose studied: 24 IU four times daily8 weeksn = 612024
No randomized trial result
3 results from other study designs.
14.4%
Mean percent change testosterone
Dose studied: 24 IUn = 452020
No randomized trial result
7 results from other study designs.
1.39 SD
effect size
n = 262017